Breathing pure oxygen during an MRI may reveal whether liver cancer treatment is working

NCT ID NCT07617038

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: Université de Montréal Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a special type of MRI, called dynamic oxygen-enhanced MRI, can predict how liver cancer responds to a treatment called transarterial chemoembolization (TACE). The MRI measures oxygen levels in tumors before and after treatment. About 60 adults with liver cancer will undergo the scan. If the technique works, it could help doctors quickly see if the treatment is effective and adjust care accordingly.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MRI contrast-enhancing agents
What this could lead to: If successful, this MRI technique could help doctors quickly tell if a liver cancer treatment is working, allowing them to adjust therapy sooner.
What could go wrong: This is a small, early-stage imaging study, not a treatment trial. The MRI method may not reliably predict response in all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma Hypoxia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HCC - HEPATOCELLULAR CARCINOMA SIRT TACE

Contacts and locations

Locations

CRCHUM

Montreal, Quebec, H2X0A9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.